News | February 11, 2022
Marksans Pharma Q3FY22 PAT at Rs. 48.27 crore
Marksans Pharma has reported consolidated financial results for the period ended December 31, 2021
Marksans Pharma has reported consolidated financial results for the period ended December 31, 2021
The product will be marketed under store brand labels and is comparable to the brand Zyrtec
Marksans Pharma has reported consolidated financial results for the period ended September 30, 2021
The company has tied up with OrbiMed as a financial partner for global reach
The shareholders have also ratified the Board’s approval to allot 10 lakhs warrants to the Promoter, Managing Director and CEO, Mark Saldanha at the said price of Rs. 74 per warrant
The company's operating revenue for Q4 FY21 was Rs. 330.2 crore
Shilpa Pharma Lifesciences, Unit-1, received EIR from USFDA
The Subsidiary has received one inspectional observation in Form 483
Alkem Medtech to acquire 100% stake of Bombay Ortho
USFDA inspection at Emcure Pharmaceuticals API facility
Subscribe To Our Newsletter & Stay Updated
